Physician profile
Amanda Wiley
NPI 1326542820
$1,262.46
in general payments reported to CMS, 2019-2025
30 companies · $17.06 in 2025
The $17.06 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $99.67 · 2022: $267 · 2023: $340 · 2024: $539 · 2025: $17.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $896.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $895.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $123.11 | 2022-2024 | |
| Alkermes, INC. | $95.15 | 2022-2023 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $73.54 | 2022-2024 | Caplyta |
| Lundbeck LLC | $71.31 | 2024 | Rexulti |
| Neurocrine Biosciences, INC. | $67.27 | 2022-2024 | Ingrezza |
| Glaxosmithkline, LLC. | $67.16 | 2022-2024 | Trelegy Ellipta, Shingrix |
| Averitas Pharma INC. | $60.88 | 2023 | Qutenza |
| Takeda Pharmaceuticals U.S.A., INC. | $56.82 | 2023-2024 | Trintellix, Glassia |
| Indivior INC. | $54.39 | 2024 | Sublocade, Perseris |
| Tris Pharma INC | $53.22 | 2024 | Dyanavel Xr |
| Lilly USA, LLC | $46.03 | 2022-2024 | Mounjaro, Trulicity |
| Janssen Pharmaceuticals, INC | $45.89 | 2024 | Spravato |
| Vanda Pharmaceuticals INC. | $39.66 | 2023 | Fanapt, Hetlioz |
| Grt US Holding, INC. | $37.97 | 2021 | |
| Novo Nordisk INC | $37.49 | 2024 | Wegovy, Ozempic |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.46 | 2021-2023 | Xifaxan, Trulance |
| Eisai INC. | $33.79 | 2024 | |
| Uswm, LLC | $31.76 | 2022 | |
| Si-Bone, INC. | $27.25 | 2021 | |
| Currax Pharmaceuticals LLC | $26.67 | 2022 | |
| Idorsia Pharmaceuticals US INC | $26.34 | 2023 | Quviviq |
| Axsome Therapeutics, INC. | $26.07 | 2024 | Sunosi |
| Teva Pharmaceuticals USA, INC. | $19.33 | 2024 | Austedo Xr |
| Astrazeneca Pharmaceuticals LP | $18.58 | 2024 | Breztri |
| Bausch Health US, LLC | $17.06 | 2025 | Wellbutrin, Aplenzin |
| Pfizer INC. | $14.65 | 2024 | |
| Hologic Sales and Service, LLC | $14.27 | 2022 | |
| Orexo US, INC. | $14.06 | 2023 | Zubsolv |
| Ibsa Pharma INC. | $13.35 | 2021 | |
| Arbor Pharmaceuticals, INC. | $12.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Wiley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.